Phase 2 N=31 Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Adult Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=282 Mucin Balls and Corneal Inflammation Events
Corneal Inflammation · Corneal Infiltrative Events
Primary: Corneal Infiltrate Events - Phase I — 18.6; 5.7 percentage of subjects
Phase 2 N=63 Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest…
Phase 2 N=52 ESBA1008 Microvolume Study
Exudative Age-Related Macular Degeneration
Primary: Percentage of Responders Based on CSFT and BCVA Outcomes at Day 14 and Day 28 — 70; 60; 80; 60 percentage of responders
Phase 2 N=50 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Hepatitis C · Cirrhosis · Portal Hypertension
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 72.0; 0; 71.4 percentage of participants
Phase 2 N=25 Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Chronic Graft-versus-host Disease
Primary: Rate of Complete Response of cGVHD to Treatment. — 84 percentage of patients — p=<0.5
Phase 2 N=105 Comparison Study of PTHrP and PTH to Treat Osteoporosis
Osteoporosis
Primary: Procallagen-1 Amino-terminal Peptide (P1NP) — 32.54; 23.51; 60.67; 48.89 percentage change from baseline — p=<0.0005
Phase 2 N=75 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
Idiopathic Thrombocytopenic Purpura
Primary: Number of Months With Platelet Response During the 12-Month Treatment Period — 9.2 months
Phase 2 N=24 A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration
Degenerative Disc Disease
Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 0 participants
Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
Phase 2 N=32 Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
Colonoscopy Preparation
Primary: Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy. — 5.7; 7.4; 7.8 units on a scale
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 2 N=32 Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Breast Cancer · Non-Hodgkin's Lymphoma
Primary: TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy — 3.55; 3.68; 2.95; 3.18 log(pg/ml) — p=0.014
Phase 2 N=29 Beating the Blues for Your Heart
Depression · Depressive Symptoms · Cardiovascular Disease (CVD)
Primary: Post-Treatment Brachial Flow-Mediated Dilation (FMD) Adjusted for Pre-Treatment FMD — 4.18; 2.47 % change in brachial diameter — p=.21
Phase 2 N=61 Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
Lung Cancer
Primary: Objective Response Rate — 3 Patients